Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age DOI Creative Commons
Yi Liu, Xinyi Chen, Theodore Evan

et al.

mAbs, Journal Year: 2025, Volume and Issue: 17(1)

Published: March 5, 2025

Folate receptor alpha (FRα) has long been the focus of therapeutics development in oncology across several solid tumors, notably ovarian, lung, and subsets breast cancers. Its multiple roles cellular metabolism carcinogenesis tumor-specific overexpression relative to normal tissues render FRα an attractive target for biological therapies. Here we review significance, expression distribution, characteristics as a highly promising now established therapy target. We discuss ongoing FRα-targeting antibodies antibody-drug conjugates (ADCs), first which approved treatment ovarian cancer, providing impetus heightened research development. Novel insights into tumor microenvironment, advances antibody engineering enhance immune-mediated effects, emergence ADCs, studies anti-FRα agents combined with chemotherapy, targeted immune are offering new perspectives possibilities. Hence, highlight key translational preclinical clinical trials interest, emphasis on combinations potential change future practice.

Language: Английский

Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age DOI Creative Commons
Yi Liu, Xinyi Chen, Theodore Evan

et al.

mAbs, Journal Year: 2025, Volume and Issue: 17(1)

Published: March 5, 2025

Folate receptor alpha (FRα) has long been the focus of therapeutics development in oncology across several solid tumors, notably ovarian, lung, and subsets breast cancers. Its multiple roles cellular metabolism carcinogenesis tumor-specific overexpression relative to normal tissues render FRα an attractive target for biological therapies. Here we review significance, expression distribution, characteristics as a highly promising now established therapy target. We discuss ongoing FRα-targeting antibodies antibody-drug conjugates (ADCs), first which approved treatment ovarian cancer, providing impetus heightened research development. Novel insights into tumor microenvironment, advances antibody engineering enhance immune-mediated effects, emergence ADCs, studies anti-FRα agents combined with chemotherapy, targeted immune are offering new perspectives possibilities. Hence, highlight key translational preclinical clinical trials interest, emphasis on combinations potential change future practice.

Language: Английский

Citations

0